Trial · NCT03137381
Adverse events160
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 160
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Upper respiratory tract infection | Infections and infestations | Combined Placebo | 7 | 44 | |
| other | Upper respiratory tract infection | Infections and infestations | Cohort 1: CTP-543 4 mg BID | 2 | 29 | |
| other | Upper respiratory tract infection | Infections and infestations | Cohort 2: CTP-543 8 mg BID | 2 | 38 | |
| other | Upper respiratory tract infection | Infections and infestations | Cohort 3: CTP-543 12 mg BID | 7 | 36 | |
| other | Nasopharyngitis | Infections and infestations | Combined Placebo | 1 | 44 | |
| other | Nasopharyngitis | Infections and infestations | Cohort 1: CTP-543 4 mg BID | 3 | 29 | |
| other | Nasopharyngitis | Infections and infestations | Cohort 2: CTP-543 8 mg BID | 3 | 38 | |
| other | Nasopharyngitis | Infections and infestations | Cohort 3: CTP-543 12 mg BID | 9 | 36 | |
| other | Folliculitis | Infections and infestations | Combined Placebo | 0 | 44 | |
| other | Folliculitis | Infections and infestations | Cohort 1: CTP-543 4 mg BID | 3 | 29 | |
| other | Folliculitis | Infections and infestations | Cohort 2: CTP-543 8 mg BID | 2 | 38 | |
| other | Folliculitis | Infections and infestations | Cohort 3: CTP-543 12 mg BID | 1 | 36 | |
| other | Sinusitis | Infections and infestations | Combined Placebo | 3 | 44 | |
| other | Sinusitis | Infections and infestations | Cohort 1: CTP-543 4 mg BID | 0 | 29 | |
| other | Sinusitis | Infections and infestations | Cohort 2: CTP-543 8 mg BID | 0 | 38 | |
| other | Sinusitis | Infections and infestations | Cohort 3: CTP-543 12 mg BID | 2 | 36 | |
| other | Influenza | Infections and infestations | Combined Placebo | 0 | 44 | |
| other | Influenza | Infections and infestations | Cohort 1: CTP-543 4 mg BID | 1 | 29 | |
| other | Influenza | Infections and infestations | Cohort 2: CTP-543 8 mg BID | 0 | 38 | |
| other | Influenza | Infections and infestations | Cohort 3: CTP-543 12 mg BID | 2 | 36 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03137381/events